بدائل البحث:
clinical decrease » clinical disease (توسيع البحث), clinical case (توسيع البحث), linear decrease (توسيع البحث)
teer decrease » greater decrease (توسيع البحث)
clinical decrease » clinical disease (توسيع البحث), clinical case (توسيع البحث), linear decrease (توسيع البحث)
teer decrease » greater decrease (توسيع البحث)
-
1
Mean scores, standard deviations, and significance on key measures and subscales by gender group.
منشور في 2025الموضوعات: -
2
-
3
-
4
-
5
-
6
-
7
B2 decreases glycolytic intermediates in cells.
منشور في 2025"…Other abbreviations: HGA, DL-hydroxyglutaric acid; PEP, phosphoenolpyruvic acid; 3-PGA, 3-phosphoglyceric acid; G3P; glyceraldehyde 3-phosphate; Data (n = 5) are shown as mean±SD. Not significant (ns): **<i>P</i> ≤ 0.01, ****<i>P</i> ≤ 0.0001by one-way ANOVA with multiple comparison of the mean of each test group to the mean of the vehicle control. …"
-
8
-
9
Cinacalcet administered early in the inactive phase markedly decrease parathyroid Ki-67 index.
منشور في 2025"…All groups were compared by Kruskal Wallis test with <i>post hoc</i> test after Dunn with Bonferroni adjustment showing significant decreased Ki-67 labeling index of <i>Cina1</i> compared to <i>Cina2</i> (p = 0.006) and the untreated CKD groups (p = 0.0001 and p = 0.0002, respectively). …"
-
10
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
منشور في 2025الموضوعات: -
11
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
منشور في 2025الموضوعات: -
12
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
منشور في 2025الموضوعات: -
13
-
14
-
15
-
16
Y-27632 collaborated with BA to attenuate the increase in the integrity and decrease in the permeability of epithelial barrier injury induced by LPS in Caco2 monolayers.
منشور في 2024"…The values are expressed as the means ± SDs and were analyzed according to the variance of the factorial design. **, *** and ****denote <i>p</i> < 0.01, < 0.001 and < 0.0001, respectively; ns = not significant.…"
-
17
-
18
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
منشور في 2025الموضوعات: -
19
Summary of post-treatment disease course measures from off-label medications clinical trials.
منشور في 2025الموضوعات: -
20
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
منشور في 2025الموضوعات: